Pfizer Ltd. | Cash Flow

Fiscal year is April-March. All values INR Millions.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
3,396
2,380
4,704
5,168
5,479
Depreciation, Depletion & Amortization
80
1,311
561
615
649
Other Funds
1,213
1,760
1,932
3,192
2,016
Funds from Operations
2,262
1,931
3,333
2,592
4,111
Changes in Working Capital
46
404
686
1,489
105
Net Operating Cash Flow
2,309
1,527
4,019
4,081
4,216
Capital Expenditures
42
206
437
253
1,027
Sale of Fixed Assets & Businesses
20
4
2
359
66
Purchase/Sale of Investments
-
-
8,327
5,020
2,656
Net Investing Cash Flow
43
70
7,573
3,289
3,281
Cash Dividends Paid - Total
13,602
14
619
826
1,104
Net Financing Cash Flow
13,602
14
619
826
1,104
Net Change in Cash
11,251
1,443
4,173
35
169
Free Cash Flow
2,266
1,321
3,582
3,828
3,335
Other Sources
64
132
1,188
1,625
336
Exchange Rate Effect
-
-
1
1
-

About Pfizer

View Profile
Address
The Capital, 1802/1901
Mumbai Maharashtra 400051
India
Employees -
Website http://www.pfizerindia.com
Updated 09/14/2018
Pfizer Ltd. (India) engages in the business of manufacturing, marketing, trading, import and export of pharmaceutical products. Its product offerings include treatment for depression, erectile dysfunction, high cholesterol, human immunodeficiency virus infection, hypertension, bacterial infections and systemic fungal infections, and other chronic therapeutic which includes pain, respiratory, vitamins or minerals, hospital anti-infectives, neurosciences, and cardiovascular. Its key products include Prevenar 13, Lyrica, Ativan, Viagra, Zosyn, Minipress XL, Meronem, Enbrel, Dolonex, Magnex, Amlogard, Trulimax, Daxid, Neksium, Becosules, Gelusil, Mucaine, Folvite, Autrin, Citralka, Corex Range, Anacin, and Anne French.